PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.10%
G&A change of 175.10% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-94.58%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-14.44%
Operating expenses reduction while AXSM shows 6.62% growth. Joel Greenblatt would examine advantage.
-14.44%
Total costs reduction while AXSM shows 8.31% growth. Joel Greenblatt would examine advantage.
4.10%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBITDA growth below 50% of AXSM's 35.57%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Operating income growth below 50% of AXSM's 35.57%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.51%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
12.51%
Net income growth 50-75% of AXSM's 19.26%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
12.37%
EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
12.37%
Diluted EPS growth 50-75% of AXSM's 20.49%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.